Premium
Single‐centre study reports a 84% five‐year overall survival rate for paediatric solid tumours
Author(s) -
Teppo Eero,
Penttinen Jarkko,
Myöhänen Outi,
Vettenranta Kim,
Lohi Olli
Publication year - 2016
Publication title -
acta paediatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/apa.13425
Subject(s) - medicine , retrospective cohort study , medical record , stage (stratigraphy) , pediatrics , cohort , referral , transplantation , survival rate , paleontology , family medicine , biology
Aim We investigated the characteristics and outcome of paediatric patients with solid tumours diagnosed and treated at the Tampere University Hospital, one of the five tertiary referral centres in Finland, for children and adolescents with malignancies. Methods This retrospective cohort study collected data from hospital medical records on survival, diagnosis, age, sex, tumour size and stage at diagnosis. We also observed the disease recurrence and use of autologous haematopoietic stem cell transplantation. Data analyses were carried out with the Kaplan–Meier method, various nonparametric and parametric tests, and Cox regression modelling. Results Between 1987 and May 2015, 424 children (59% boys), with a median age of 6.4 ( IQR 2.5–11.8) years at diagnosis, were diagnosed and followed up for a median of 7.5 (range 0‐27.9) years. Central nervous system ( CNS ) tumours were the most common (38%), followed by lymphomas (19%), soft tissue sarcomas (10%), renal tumours (9%) and neuroblastomas (9%). The five‐year overall survival rate of all solid tumour patients was 84% (95% CI , 81–88%), 82% (95% CI , 76–89%) for CNS and 85% (95% CI , 80‐90%) for non‐ CNS tumours. Advanced tumour stage at diagnosis predicted a poor prognosis. Conclusion The treatment results in our study are comparable with those previously published. A comprehensive local database allows for a timely follow‐up of the characteristics and quality of treatment of childhood malignancies.